Atea 未达到收益，但因 COVID-19 药物进展而股价上涨;Acurx 股价下跌，跌幅小于预期。 Atea missed earnings but saw stock rise on COVID-19 drug progress; Acurx lost less than expected as its stock fell.

Atea制药公司报告,每股季度损失0.53美元,损失估计数缺失,其库存量高于平均水平,上升至3.50美元。 Atea Pharmaceuticals reported a quarterly loss of $0.53 per share, missing estimates, while its stock rose to $3.50 on higher-than-average volume. 该公司在第三阶段试验中正在推进其COVID-19药物AT-527。 The company is advancing its COVID-19 drug AT-527 in Phase 3 trials. Acurx制药公司的损失小于预期,每股1.23美元,但其库存低于平均水平,跌至5.06美元。 Acurx Pharmaceuticals posted a smaller loss than expected at $1.23 per share, but its stock fell to $5.06 on below-average volume. Acurx的抗生性Ibezapolstat 正处于二B阶段, Acurx’s antibiotic ibezapolstat is in Phase 2b trials for Clostridium difficile infections. 这两家公司仍然无利可图,Atea的机构所有权占87%,Acurx占12%。 Both companies remain unprofitable, with institutional ownership at 87% for Atea and 12% for Acurx.